Three epilepsy medications are most consistently linked to weight loss: topiramate (Topamax), zonisamide (Zonegran), and felbamate (Felbatol). Of these, topiramate produces the most pronounced and well-documented effect, with patients losing an average of 3.9% of their body weight within three months and 7.3% within a year. Several other seizure medications, including rufinamide, stiripentol, cannabidiol, and ethosuximide, can also decrease appetite and lead to some weight loss, though the data on those is less robust.
Topiramate: The Strongest Effect
Topiramate is the epilepsy drug most closely associated with weight loss, and it’s the only one that has crossed over into dedicated weight management use (in combination with phentermine, sold as Qsymia). For people taking it for seizures, the weight loss is a side effect, not the goal, but it’s significant enough to notice.
In a prospective trial of patients adding topiramate to their existing seizure medication, mean body weight dropped by 3.9% at three months and 7.3% at one year. For patients who started with a BMI over 30, the effect was even larger: 4.3% loss at three months and about 10.9 kg (roughly 24 pounds) at one year. People who lost 10% or more of their body weight also saw a 36% drop in leptin, a hormone that regulates hunger and energy balance.
Topiramate appears to drive weight loss through several overlapping pathways. It disrupts how efficiently your body stores energy, essentially burning more calories through increased heat production in fat tissue and muscle. It also inhibits an enzyme involved in creating new fat cells. Beyond metabolism, topiramate seems to alter how the brain’s reward system responds to food, reducing binge eating behavior and compulsive food-seeking. It can also lower fasting blood sugar, cholesterol, and triglycerides, changes that reflect a broader shift in how the body handles energy.
One additional quirk: topiramate is a carbonic anhydrase inhibitor, a property it shares with the altitude sickness drug acetazolamide. This class of drugs changes how carbonated drinks taste, making them seem flat and unappealing. Carbonic anhydrase inhibition may also suppress appetite by interfering with ghrelin, a hormone that triggers hunger signals in your gut. So if you’re on topiramate and your favorite soda suddenly tastes wrong, that’s the drug at work.
Zonisamide: Steady, Gradual Loss
Zonisamide produces meaningful weight loss, though the timeline is slower than topiramate. In a randomized controlled trial, people taking zonisamide lost an average of 5.9 kg (about 13 pounds), or 6% of their body weight, over 16 weeks. The placebo group lost less than 1 kg over the same period. By week 32, the zonisamide group had lost 9.2 kg (about 20 pounds), representing a 9.4% reduction in body weight.
The response rate is also notable: 57% of people on zonisamide lost at least 5% of their body weight within 16 weeks, compared to just 10% in the placebo group. Like topiramate, zonisamide is a carbonic anhydrase inhibitor, which likely contributes to its appetite-suppressing and metabolic effects through similar pathways.
Felbamate: Modest but Measurable
Felbamate causes less dramatic weight loss than topiramate or zonisamide, but it’s consistent enough to be clinically recognized. In clinical trials, both adults and children experienced an average weight reduction of about 5% from their baseline. Weight decrease was reported as a side effect in about 3.4% of adults and 6.5% of children in controlled trials.
Felbamate is worth knowing about because it’s sometimes used for Lennox-Gastaut syndrome, a severe form of childhood epilepsy. In that population, the combination of appetite suppression and weight loss needs careful monitoring, since children are still growing. That said, felbamate carries serious safety warnings for other reasons (rare but potentially fatal blood and liver problems), so it’s typically reserved for cases where other medications haven’t worked.
Other Seizure Medications That Reduce Appetite
Beyond the big three, several other anti-seizure drugs are associated with decreased appetite or weight loss in clinical practice. These include fenfluramine, rufinamide, stiripentol, cannabidiol (Epidiolex), brivaracetam, and ethosuximide. The weight loss effects of these medications tend to be less predictable and less well-quantified than topiramate or zonisamide, and they’re often prescribed for specific epilepsy syndromes rather than as general-purpose seizure drugs.
Which Epilepsy Drugs Don’t Affect Weight
If you’re concerned about weight changes in either direction, it helps to know which options are considered weight-neutral. Lamotrigine (Lamictal), levetiracetam (Keppra), and phenytoin (Dilantin) generally don’t cause meaningful weight gain or loss. These are sometimes preferred when a patient is already underweight or when weight stability is a priority.
On the other end of the spectrum, valproate (Depakote), carbamazepine, gabapentin, and pregabalin are the epilepsy drugs most associated with weight gain. If you’re switching medications and weight is a concern, the gap between a drug like valproate and one like topiramate can be substantial, sometimes 10 kg or more in opposite directions over a year.
Why This Matters for Your Treatment
Weight loss from epilepsy drugs isn’t always welcome. If you’re already at a healthy weight or underweight, losing 5 to 10% of your body weight can cause fatigue, muscle loss, and nutritional deficiencies. For children, it can interfere with normal growth and development. Multiple factors beyond medication affect weight in people with epilepsy, including seizure frequency, activity levels, and other drugs in their regimen, so isolating the cause of weight changes isn’t always straightforward.
For people who are overweight, though, the weight loss side effect of topiramate or zonisamide can genuinely be a benefit, sometimes influencing which drug a neurologist recommends. The weight loss from these drugs tends to plateau after 12 to 18 months rather than continuing indefinitely, and it typically reverses if the medication is stopped. If you’re experiencing unwanted weight loss on any of these drugs, tracking your weight over a few months gives you and your doctor useful data to decide whether a dose adjustment or medication switch makes sense.